{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:37:28Z","timestamp":1760143048548,"version":"build-2065373602"},"reference-count":57,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T00:00:00Z","timestamp":1705190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Multiple myeloma is a hematologic neoplasm caused by abnormal proliferation of plasma cells. Sequencing studies suggest that plasma cell disorders are caused by both cytogenetic abnormalities and oncogene mutations. Therefore, it is necessary to detect molecular abnormalities to improve the diagnosis and management of MM. The main purpose of this study is to determine whether NGS, in addition to cytogenetics, can influence risk stratification and management. Additionally, we aim to establish whether mutational analysis of the CD138 cell population is a suitable option for the characterization of MM compared to the bulk population. Following the separation of the plasma cells harvested from 35 patients newly diagnosed with MM, we performed a FISH analysis to detect the most common chromosomal abnormalities. Consecutively, we used NGS to evaluate NRAS, KRAS, BRAF, and TP53 mutations in plasma cell populations and in bone marrow samples. NGS data showed that sequencing CD138 cells provides a more sensitive approach. We identified several variants in BRAF, KRAS, and TP53 that were not previously associated with MM. Considering that the presence of somatic mutations could influence risk stratification and therapeutic approaches of patients with MM, sensitive detection of these mutations at diagnosis is essential for optimal management of MM.<\/jats:p>","DOI":"10.3390\/cancers16020358","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T04:54:38Z","timestamp":1705294478000},"page":"358","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["DNA Sequencing of CD138 Cell Population Reveals TP53 and RAS-MAPK Mutations in Multiple Myeloma at Diagnosis"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8529-1107","authenticated-orcid":false,"given":"Mihaela","family":"Dragomir","sequence":"first","affiliation":[{"name":"Faculty of Biology, University of Bucharest, 030018 Bucharest, Romania"},{"name":"Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onda-Tabita","family":"C\u0103lug\u0103ru","sequence":"additional","affiliation":[{"name":"Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogdan","family":"Popescu","sequence":"additional","affiliation":[{"name":"Hematology Department, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cerasela","family":"Jardan","sequence":"additional","affiliation":[{"name":"Fundeni Clinical Institute, 022328 Bucharest, Romania"},{"name":"Hematology Department, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dumitru","family":"Jardan","sequence":"additional","affiliation":[{"name":"Molecular Biology Laboratory, Medlife Bucharest, 010093 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Popescu","sequence":"additional","affiliation":[{"name":"Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Aposteanu","sequence":"additional","affiliation":[{"name":"Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1507-2547","authenticated-orcid":false,"given":"Sorina","family":"B\u0103deli\u021b\u0103","sequence":"additional","affiliation":[{"name":"Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Nedelcu","sequence":"additional","affiliation":[{"name":"Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u0103t\u0103lin","family":"\u0218erban","sequence":"additional","affiliation":[{"name":"Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Codru\u021ba","family":"Popa","sequence":"additional","affiliation":[{"name":"Fundeni Clinical Institute, 022328 Bucharest, Romania"},{"name":"Hematology Department, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana","family":"Vassu-Dimov","sequence":"additional","affiliation":[{"name":"Faculty of Biology, University of Bucharest, 030018 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Coriu","sequence":"additional","affiliation":[{"name":"Fundeni Clinical Institute, 022328 Bucharest, Romania"},{"name":"Hematology Department, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,14]]},"reference":[{"key":"ref_1","unstructured":"American Cancer Society (2023, August 08). Survival Rates for Multiple Myeloma. Available online: https:\/\/www.cancer.org\/cancer\/types\/multiple-myeloma\/detection-diagnosis-staging\/survival-rates.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1038\/bcj.2015.92","article-title":"Interpretation of Cytogenetic Results in Multiple Myeloma for Clinical Practice","volume":"5","author":"Rajan","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Wiedmeier-Nutor, J.E., and Bergsagel, P.L. (2022). Review of Multiple Myeloma Genetics Including Effects on Prognosis, Response to Treatment, and Diagnostic Workup. Life, 12.","DOI":"10.3390\/life12060812"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple Myeloma: 2022 Update on Diagnosis, Risk Stratification, and Management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e537","DOI":"10.1038\/bcj.2017.19","article-title":"Mutational Landscape Reflects the Biological Continuum of Plasma Cell Dyscrasias","volume":"7","author":"Rossi","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jmoldx.2017.01.011","article-title":"Guidelines for Validation of Next-Generation Sequencing\u2013Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists","volume":"19","author":"Jennings","year":"2017","journal-title":"J. Mol. Diagn."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J. Mol. Diagn."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"2","author":"Dimopoulos","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","article-title":"Clonal Selection and Double-Hit Events Involving Tumor Suppressor Genes Underlie Relapse in Myeloma","volume":"128","author":"Weinhold","year":"2016","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Chen, S., Francioli, L.C., Goodrich, J.K., Collins, R.L., Kanai, M., Wilson, M.W., Tarasova, Y., Phu, W., Yohannes, M.T., and Koenig, Z. (2022). A Genome-Wide Mutational Constraint Map Quantified from Variation in 76,156 Human Genomes. bioRxiv.","DOI":"10.1101\/2022.03.20.485034"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1016\/j.sjbs.2021.04.089","article-title":"Analysis of RAS Gene Mutations in Cytogenetically Normal de Novo Acute Myeloid Leukemia Patients Reveals Some Novel Alterations","volume":"28","author":"Akram","year":"2021","journal-title":"Saudi J. Biol. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ajh.26731","article-title":"Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia across Therapy Subtypes","volume":"97","author":"Rivera","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2147\/OTT.S265637","article-title":"Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments","volume":"15","author":"Granowicz","year":"2022","journal-title":"Onco. Targets. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular Characterization of Mutant TP53 Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 Mutations in AML: Review of Current Knowledge and Evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.esmoop.2023.100788","article-title":"Precision Oncology for BRAF-Mutant Cancers with BRAF and MEK Inhibitors: From Melanoma to Tissue-Agnostic Therapy","volume":"8","author":"Gouda","year":"2023","journal-title":"ESMO Open"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.18632\/oncotarget.27304","article-title":"The Multifaceted Anti-Cancer Effects of BRAF-Inhibitors","volume":"10","author":"Croce","year":"2019","journal-title":"Oncotarget"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Proietti, I., Skroza, N., Michelini, S., Mambrin, A., Balduzzi, V., Bernardini, N., Marchesiello, A., Tolino, E., Volpe, S., and Maddalena, P. (2020). BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions. Cancers, 12.","DOI":"10.3390\/cancers12071823"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.15252\/embj.201592097","article-title":"Activation Loop Phosphorylation Regulates B-Raf in Vivo and Transformation by B-Raf Mutants","volume":"35","author":"Schorch","year":"2016","journal-title":"EMBO J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e12814","DOI":"10.7554\/eLife.12814","article-title":"The Yin-Yang of Kinase Activation and Unfolding Explains the Peculiarity of Val600 in the Activation Segment of BRAF","volume":"5","author":"Kiel","year":"2016","journal-title":"Elife"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","article-title":"Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF","volume":"116","author":"Wan","year":"2004","journal-title":"Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/sj.onc.1210704","article-title":"BRAFE600 in Benign and Malignant Human Tumours","volume":"27","author":"Michaloglou","year":"2008","journal-title":"Oncogene"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"882940","DOI":"10.3389\/fonc.2022.882940","article-title":"The Evolution of BRAF Activation in Non-Small-Cell Lung Cancer","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1158\/1078-0432.CCR-18-2062","article-title":"Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-Mutant Lung Cancer","volume":"25","author":"Martinez","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Kim, N., Shin, I., Lee, J., Jeon, E., Kim, Y., Ryu, S., Ju, E., Cho, W., and Sim, T. (2021). Novel and Potent Small Molecules against Melanoma Harboring Braf Class i\/Ii\/Iii Mutants for Overcoming Drug Resistance. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22073783"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF Gene in Human Cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1399-0004.2010.01495.x","article-title":"Germline Mutation in BRAF Codon 600 Is Compatible with Human Development: De Novo p.V600G Mutation Identified in a Patient with CFC Syndrome","volume":"79","author":"Champion","year":"2011","journal-title":"Clin. Genet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"547127","DOI":"10.3389\/fonc.2020.01056","article-title":"A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report","volume":"10","author":"Consoli","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000500481","article-title":"Lack of Response to Vemurafenib in Melanoma Carrying BRAF K601E Mutation","volume":"12","author":"Moiseyenko","year":"2019","journal-title":"Case Rep. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1200\/PO.20.00187","article-title":"Targeted Therapy in BRAF p.K601E\u2013Driven NSCLC: Case Report and Literature Review","volume":"5","author":"Saalfeld","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"ref_31","first-page":"100202","article-title":"Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report","volume":"2","author":"Su","year":"2021","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40164-017-0067-4","article-title":"Metastatic BRAF K601E-Mutated Melanoma Reaches Complete Response to MEK Inhibitor Trametinib Administered for over 36 Months","volume":"6","author":"Marconcini","year":"2017","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1089\/thy.2015.0227","article-title":"Histopathologic and Clinical Characterization of Thyroid Tumors Carrying the BRAFK601E Mutation","volume":"26","author":"Afkhami","year":"2016","journal-title":"Thyroid"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1002\/cam4.3103","article-title":"BRAF Mutation and Its Inhibitors in Sarcoma Treatment","volume":"9","author":"Liu","year":"2020","journal-title":"Cancer Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e246264","DOI":"10.1136\/bcr-2021-246264","article-title":"Partial Response to Dabrafenib and Trametinib in Relapsed BRAF V600E-Mutated Multiple Myeloma and Possible Mechanisms of Resistance","volume":"15","author":"Ernst","year":"2022","journal-title":"BMJ Case Rep."},{"key":"ref_36","first-page":"00070","article-title":"Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-BASKET Study","volume":"2","author":"Raje","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1182\/blood.2022017789","article-title":"A Phase 2 Clinical Trial of Combined BRAF\/MEK Inhibition for BRAFV600E-Mutated Multiple Myeloma","volume":"14","author":"Giesen","year":"2023","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"9251","DOI":"10.18632\/oncotarget.14002","article-title":"LY3009120, a PanRAF Inhibitor, Has Significant Anti-Tumor Activity in BRAF and KRAS Mutant Preclinical Models of Colorectal Cancer","volume":"8","author":"Vakana","year":"2017","journal-title":"Oncotarget"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"109157","DOI":"10.1016\/j.celrep.2021.109157","article-title":"A Systematic Analysis of Signaling Reactivation and Drug Resistance","volume":"35","author":"Kholodenko","year":"2021","journal-title":"Cell Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients with Newly Diagnosed Myeloma","volume":"33","author":"Walker","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"20004","DOI":"10.1073\/pnas.2005052117","article-title":"Activating KRAS, NRAS, and BRAF Mutants Enhance Proteasome Capacity and Reduce Endoplasmic Reticulum Stress in Multiple Myeloma","volume":"117","author":"Shirazi","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1182\/blood.2020010572","article-title":"Specific Targeting of the KRAS Mutational Landscape in Myeloma as a Tool to Unveil the Elicited Antitumor Activity","volume":"138","author":"Sacco","year":"2021","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.csbj.2019.12.004","article-title":"The Current Understanding of KRAS Protein Structure and Dynamics","volume":"18","author":"Pantsar","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Sriskandarajah, P., De Haven Brandon, A., MacLeod, K., Carragher, N.O., Kirkin, V., Kaiser, M., and Whittaker, S.R. (2020). Combined Targeting of MEK and the Glucocorticoid Receptor for the Treatment of RAS-Mutant Multiple Myeloma. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-06735-2"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/S1470-2045(20)30464-2","article-title":"Intermittent Schedules of the Oral RAF\u2013MEK Inhibitor CH5126766\/VS-6766 in Patients with RAS\/RAF-Mutant Solid Tumours and Multiple Myeloma: A Single-Centre, Open-Label, Phase 1 Dose-Escalation and Basket Dose-Expansion Study","volume":"21","author":"Guo","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.clml.2022.10.006","article-title":"Cobimetinib Alone and Plus Venetoclax With\/Without Atezolizumab in Patients With Relapsed\/Refractory Multiple Myeloma","volume":"23","author":"Schjesvold","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","article-title":"The Current State of the Art and Future Trends in RAS-Targeted Cancer Therapies","volume":"19","author":"Punekar","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.3389\/fonc.2019.01137","article-title":"Kras\/Nras\/Braf Mutations as Potential Targets in Multiple Myeloma","volume":"9","author":"Pasca","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1158\/2159-8290.CD-13-0014","article-title":"Targeting the BRAF V600E Mutation in Multiple Myeloma","volume":"3","author":"Andrulis","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1158\/2159-8290.CD-13-0297","article-title":"Targeting BRAF in Multiple Myeloma","volume":"3","author":"Raje","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood.2020008346","article-title":"Del(17p) without TP53 Mutation Confers a Poor Prognosis in Intensively Treated Newly Diagnosed Patients with Multiple Myeloma","volume":"137","author":"Corre","year":"2021","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1093\/jnci\/djab019","article-title":"Effect of the P53 P72R Polymorphism on Mutant TP53 Allele Selection in Human Cancer","volume":"113","author":"Madden","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood.2021013983","article-title":"TP53 Copy Number and Protein Expression Inform Mutation Status across Risk Categories in Acute Myeloid Leukemia","volume":"140","author":"Tashakori","year":"2022","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1182\/hematology.2022000347","article-title":"High or Low? Assessing Disease Risk in Multiple Myeloma","volume":"2022","author":"Schmidt","year":"2022","journal-title":"Hematology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"932852","DOI":"10.3389\/fonc.2022.932852","article-title":"Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy","volume":"12","author":"Ferla","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00109-020-01897-9","article-title":"Liquid biopsies for multiple myeloma in a time of precision medicine","volume":"98","author":"Ferreira","year":"2020","journal-title":"J. Mol. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"852573","DOI":"10.3389\/fonc.2022.852573","article-title":"Clinical Significance of Circulating Cell-Free DNA Detection in Multiple Myeloma: A Meta-Analysis","volume":"12","author":"Ye","year":"2022","journal-title":"Front. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/2\/358\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:46:25Z","timestamp":1760103985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/2\/358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,14]]},"references-count":57,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["cancers16020358"],"URL":"https:\/\/doi.org\/10.3390\/cancers16020358","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2024,1,14]]}}}